Medical treatment of canine pituitary-dependent hyperadrenocorticism (Cushing's disease)

Vet Clin North Am Small Anim Pract. 2001 Sep;31(5):1005-14, viii. doi: 10.1016/s0195-5616(01)50010-8.

Abstract

Pituitary-dependent hyperadrenocorticism (Cushing's disease) is a relatively common endocrine disorder of middle- to old-age dogs. Three treatments commonly used in the management of pituitary-dependent Cushing's disease in dogs include mitotane, ketoconazole, and L-deprenyl. These medications are associated with the potential of different side effects and expense, but all can produce satisfactory results in dogs with this disease. The choice of treatment for a given dog depends on the severity of the dog's disease, as well as clinician and client preferences. This article reviews the indications and adverse effects associated with each of these three drugs, as well as the treatment protocols commonly used in treating dogs with hyperadrenocorticism.

Publication types

  • Review

MeSH terms

  • Animals
  • Antifungal Agents / therapeutic use
  • Cushing Syndrome / drug therapy
  • Cushing Syndrome / veterinary*
  • Dog Diseases / drug therapy*
  • Dogs
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Ketoconazole / adverse effects
  • Ketoconazole / therapeutic use
  • Mitotane / adverse effects
  • Mitotane / therapeutic use*
  • Monoamine Oxidase Inhibitors / adverse effects
  • Monoamine Oxidase Inhibitors / therapeutic use*
  • Pituitary Diseases / drug therapy
  • Pituitary Diseases / veterinary*
  • Pituitary Gland / pathology
  • Selegiline / adverse effects
  • Selegiline / therapeutic use*
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Monoamine Oxidase Inhibitors
  • Selegiline
  • Mitotane
  • Ketoconazole